GSK to provide services for Novavax's COVID-19 vaccine in the U.K.

By The Science Advisory Board staff writers

March 30, 2021 -- GlaxoSmithKline (GSK) has signed an agreement in principle to support manufacturing of up to 60 million doses of Novavax's NVX-CoV2373 COVID-19 vaccine candidate for use in the U.K.

Beginning as early as May, GSK will provide fill and finish manufacturing capacity at its Barnard Castle facility in the northeast of England. The parties, which include GSK, Novavax, and the U.K. Government Vaccines Taskforce, will negotiate a final agreement to include additional terms and conditions, GSK said.

The vaccine is expected to be submitted for regulatory review in the U.K. during the second quarter.

If you like this content, please share it with a colleague!

Related Reading

GSK, Vir file EUA submission for COVID-19 mAb treatment
GlaxoSmithKline (GSK) and Vir Biotechnology filed an emergency use authorization (EUA) application with the U.S. Food and Drug Administration for VIR-7831...

Medicago, GSK start phase III of COVID-19 vaccine trial
Medicago and GlaxoSmithKline (GSK) have started phase III of their adjuvanted COVID-19 vaccine candidate clinical trial.

Vir, GSK prepare to submit anti-COVID-19 mAb EUA
Vir Biotechnology and GlaxoSmithKline (GSK) are moving ahead with regulatory submission of their COVID-19 monoclonal antibody (mAb), VIR-7831, after a...

GSK, Vir partner on infectious diseases therapies
GlaskoSmithKline (GSK) and Vir Biotechnology have signed a deal to research and develop new therapies for influenza and other respiratory viruses.

GSK, CureVac collaborate on next-gen multivalent mRNA COVID-19 vaccines
Glaxo Smith Kline (GSK) and CureVac have entered into a collaboration to jointly develop next-generation messenger RNA (mRNA) vaccines for COVID-19, with...